# Trade Mark Journal No.2025/024 13 June 2025

## WO0000001855735 (5,42)

Office of origin: United States of America

Date of International Registration:10 March 2025
Date of designation in the UK: 10 March 2025

International priority date claimed: 11 September 2024 (United States of America) (98745375)
International priority date claimed: 8 March 2025 (United States of America) (99074324)

Class 5
  Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical preparations and substances for the treatment of autoimmune diseases and disorders, autoimmune deficiency; pharmaceutical preparation and substances for the treatment of genetic disorders; pharmaceutical preparations and substances for the treatment of metabolic diseases; pharmaceutical preparations and substances for the treatment of neurodegenerative diseases; pharmaceutical preparations and substances for the treatment of kidney diseases; diagnostic biomarker reagents for medical purposes; protein arrays for medical diagnosis purposes; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic preparations for medical purposes for detecting the presence of tumors, genetic disorder and autoimmune disorders and conditions; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders, autoimmune deficiency; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the treatment of metabolic diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of eye diseases; pharmaceutical preparations for the treatment of cardiovascular diseases; diagnostic biomarker reagents for medical purposes; protein arrays for medical diagnosis purposes; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic preparations for medical purposes; pharmaceutical preparations for the treatment of oncological diseases and disorders, autoimmune diseases and disorders, autoimmune deficiency, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, cardiovascular diseases; all of the foregoing excluding treatments and diagnostics for neuromuscular disorders and orphan diseases.
Class 42
  Research and development services in the field of biologics, namely, antibodies and peptides for the treatment of cancer and immunotherapies; research and development in the pharmaceutical and biotechnology fields for the treatment of cancer and immunotherapies; providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the field of cancer and immunotherapies; consulting services in the fields of biotechnology, pharmaceutical research and development, and pharmacogenetics in the field of cancer and immunotherapies; conducting research for others in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of cancer and immunotherapies; research and development services in the field of biologics, namely, antibodies and peptides for the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; research and development in the pharmaceutical and biotechnology fields for the treatment of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; consulting services in the fields of biotechnology, pharmaceutical research and development, and pharmacogenetics in the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; conducting research for others in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of autoimmune diseases, autoimmune disorders, metabolic diseases, neurodegenerative diseases, and kidney diseases; pharmaceutical research and development; research and development in the field of biologics, namely, antibodies and peptides for the field of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, and cardiovascular diseases; research and development in the field of pharmaceuticals, biopharmaceuticals, and biotechnologies for the treatment of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, and cardiovascular diseases; research and development in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases eye diseases, and cardiovascular diseases; providing medical and scientific research information; consulting services in the field of pharmaceutical research and development; consulting services in the field of biotechnology; consulting services in the field of pharmacogenetics; research and development in the field of oncological diseases and disorders, autoimmune diseases and disorders, autoimmune deficiency, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, cardiovascular diseases; all of the foregoing excluding treatments and diagnostics for neuromuscular disorders and orphan diseases.

DynamiCure Biotechnology, LLC

Representative: Keith Toms, Esq. McCarter & English, LLP, 265 Franklin Street, Boston MA 02110-3113, UNITED STATES OF AMERICA